Myocarditis after RNA-based vaccines for coronavirus.
Int J Cardiol
; 353: 131-134, 2022 04 15.
Article
in English
| MEDLINE | ID: covidwho-1652578
ABSTRACT
BACKGROUND:
The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest.METHODS:
We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12-17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators.RESULTS:
We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034-0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19). CONCLUSIONS AND RELEVANCE Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Myocarditis
Type of study:
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Topics:
Vaccines
Limits:
Adolescent
/
Child
/
Humans
Language:
English
Journal:
Int J Cardiol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS